AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03085849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110
Description: SC daily for 5 days (days 1-5) until progression or toxicity~Dose escalation scheme:~Dose level -1 - SGI-110 20 mg/m2 SC daily; Dose level 0 - SGI-110 30 mg/m2 SC daily; Dose level 1 - SGI-110 45 mg/m2 SC daily; and SGI-110 given on days 1-5 of every 28 day cycle
Study NCT06251531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-Directed Therapist-Guided Play-Based Intervention (GD-TG-PBI)
Description: The GD-TG-PBI used play to improve performance in targeted functional activities. The program was planned by a physiotherapist with 25 years' experience and an occupational therapist with six years' experience in play. The sessions were based on motor-learning principles supporting cortical plasticity. Individual-specific goals were transformed into play activities that increase occupational participation with regard to the child's abilities, needs, and learning potential. A top-down approach based on direct gamification was adapted without dividing it into components, instead of a component-based, bottom-up approach. Thus, a structured play program was created and an individual-specific intervention was applied in line with the occupational goals and detailed motor evaluations. Positive, active experiences facilitated the adaptation of the learned skills to daily life.
Study NCT02638454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Resistance Exercise
Description: 1 bout of high-intensity resistance exercise at 80% of the individuals 1 repetition maximum
Study NCT02638454 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acute Resistance Exercise
Description: 1 bout of high-intensity resistance exercise at 80% of the individuals 1 repetition maximum
Study NCT03609216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Undergo chemoradiotherapy
Study NCT00556790 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Care
Description: standard fluid regime, delayed feeding
Study NCT00556790 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fast Track care
Description: restrictive fluid regime, early oral feeding, enforced mobilisation
Study NCT03521856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: shoulder exercise
Description: Exercises performed 3 times a week for 12 weeks
Study NCT05025319 — intervention group
Intervention type: RADIATION
Intervention: X-ray image
Description: Bedside x-ray at intensive unit.
Study NCT04215965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biphozyl (dialysate and replacement)
Description: Replacement solution with phosphate and without calcium in CRRT with citratre-based antigoagulation
Study NCT04215965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prismocal B22 (dialysate) + phoxilium (replacement)
Description: solution with phosphate and calcium in CRRT with citratre-based antigoagulation
Study NCT02319044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 monotherapy
Study NCT03521856 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education
Study NCT01103024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Study NCT01103024 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03701035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training & UL Motor Training
Description: Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if \< 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
Study NCT03701035 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-aerobic training & UL Motor Training
Description: 40 minutes non-aerobic gait \& balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
Study NCT02604901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening and Brief Intervention (BI)
Description: Rite Aid® pharmacists screened patients at the time of the initial fill with the Adherence Estimator™ and using the screening results, provided the behavioral intervention, Brief Intervention using motivational interviewing principles based on POLAR\*S (BI). BI was considered an active intervention method.
Study NCT02319044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab monotherapy
Study NCT02604901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pill Box (PB)
Description: Rite Aid® pharmacists provided patients with a Pill Box (PB) and information about their medications. However, pharmacists did not use motivational interviewing principles for engaging patients in direct interventions to modify behavior. PB was considered a passive intervention method.
Study NCT02319044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 + Tremelimumab
Description: MEDI4736 + Tremelimumab combination therapy
Study NCT02317562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I10E
Description: Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 45 weeks.
Study NCT01528267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous blood
Description: 50mls of autologous blood injected into each of 3 bronchopulmonary segments.
Study NCT01528267 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: 50mls of normal saline injected into each of 3 bronchopulmonary segments.
Study NCT01886599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir
Study NCT01929304 — intervention group
Intervention type: OTHER
Intervention: Survey
Study NCT00620243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1: FDG PET
Description: The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
Study NCT04563065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation and final talk (comments and sharing) will be performed (12-15 minutes).
Study NCT04563065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle advise
Description: This intervention consists of providing infographics and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations and fundamental exercises to perform during pregnancy.
Study NCT04041895 — intervention group
Intervention type: OTHER
Intervention: Audio speech recording
Description: Audio recording of speech sample from subject description of Cookie-Theft image.
Study NCT02658812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02658812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given IT
Study NCT00902603 — intervention group
Intervention type: DRUG
Intervention: Commercial Ventavis® (iloprost)
Description: Commercial Ventavis® (iloprost) administered via portable nebulizer (I-neb® AAD® system using the power disc-6)
Study NCT04307238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PLR
Description: PLR measurements will be performed within the first 2 postoperative hours.
Study NCT04307238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Alertness testing
Description: Preoperative (baseline) and every 30 minutes postoperative computer based alertness testing will be performed.
Study NCT04307238 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Propofol anesthesia
Description: Maintenance of anesthesia will be performed using propofol.
Study NCT04307238 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sevoflurane anesthesia
Description: Maintenance of anesthesia will be performed using sevoflurane.
Study NCT01814163 — intervention group
Intervention type: DRUG
Intervention: paclitaxel, carboplatin and bevacizumab
Description: Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
Study NCT03299803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Men's Healing Pathways
Description: Peer implemented group self management program to reduce depressive symptoms in men with physical disabilities
Study NCT01660217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A written Eczema Action Plan (EAP)
Description: A written Eczema Action Plan (EAP) was given to the patients with their treatment regimen.
Study NCT03682315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic phycogenic biomaterial
Description: Maxillary sinus floor elevation and bone grafting with the use of biphasic phycogenic biomaterial combined with autogenous cortical bone
Study NCT03682315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xenograft bovine hydroxyapatite
Description: Maxillary sinus floor elevation and bone grafting with the use of xenograft bovine hydroxyapatite combined with autogenous cortical bone
Study NCT01625520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230 alone or in combination with RAD001.
Description: SOM230 (pasireotide) 60 mg i.m. injection once every 28 days, +/- 2 days. RAD001 (everolimus) 10 mg per os daily.
Study NCT02409238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin dosage schedule: 250 mg thrice a day titrated from 250 mg once a day. Patients will first be started on Metformin 250 mg once a day with meals, and the dose increased to 250 mg twice a day at Day 8, to 250 mg three times a day at Day 15, subject to reports of poor tolerance of gastrointestinal symptoms or other side effects.
Study NCT00567177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis, Refresh Plus
Description: Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
Study NCT00567177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Restasis, Refresh Plus
Description: Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
Study NCT01520623 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Serum concentration /Serum inflammatory
Description: Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
Study NCT03621800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol popsicle
Description: The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 20ml ultrafiltered water and 2% cereal alcohol. The menthol popsicle was supported by a stick, allowing patients to taste more comfortably, with autonomy and safety
Study NCT02627209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spectrophotometric assay
Description: measurement of enzyme activity in the serum
Study NCT02627209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: radial immunodiffusion
Description: measurement of the precipitated ring diameters showing enzyme activity in the serum
Study NCT03755609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 0.1 mg/kg intravenously
Study NCT03755609 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: fentanyl
Description: 1ug/kg intravenously
Study NCT02729376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: galeterone
Study NCT02032888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study NCT02409238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Description: The intensive lifestyle interventions for the Active Intervention groups will be done at the Lifestyle Intervention Centres. The aim would to achieve and maintain a weight reduction of at least 7 percent of initial body weight through a healthy reduced-calorie, low-fat diet and engagement in physical activity of moderate intensity for at least 150 minutes per week.~This will be accomplished through a programme of individualized fitness assessment and exercise prescription for cardiovascular, strength and functional training that is standardized across study sites and facilities. The programme comprises an initial 32 sessions (2 times weekly) for supervised gym workout over 16 weeks, followed by maintenance programme of regular unsupervised exercises.
Study NCT02409238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard LIfestyle Recommendation
Description: The standard lifestyle recommendations for the Control groups are in the form of standard diabetic education pamphlets and a 20-to-30-minute individual session that emphasizes the importance of a healthy lifestyle to reduce their weight and to increase their physical activity. Activity will be monitored using a pedometer.
Study NCT02032888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Study NCT03963206 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cabozantinib group
Description: The patient starts at 60 mg / day at a distance from meals In the event of intolerance to this dose of 60 mg; specific adapted measures will be taken according to the recommendations of the good practices of use of Cabozantinib within the framework of its MA. If the symptomatic treatments are not enough, each investigator can adapt the dose of Cabozantinib reducing it to 40 or even 20 mg / day Cabozantinib will be continued for as long as radiological and / or clinical benefit is observed for the patient (no progression of the disease) or until the occurrence of unacceptable toxicity.
Study NCT03923179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib, 400mg qd
Study NCT03923179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide, 50mg，qd,d1-21,Q4W
Study NCT00803764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Tablets, 500 mg
Study NCT03902028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reinforced multidisciplinary follow-up
Description: Reinforced multidisciplinary follow-up
Study NCT00487500 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Description: Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure
Study NCT00487500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Description: Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure
Study NCT02559700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain training programme
Description: An online package of brain training programmes
Study NCT03168958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone will be provided at induction of anesthesia
Study NCT03168958 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline will be administered at induction of anesthesia
Study NCT04330729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Se arm description
Study NCT04020861 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active PBM
Description: To active photobiomodulation therapy (PBMT) the patient will be oriented to lie preferably in prone. The treatment area will be defined according to painful area. In the active group will be used the followings parameters: low-level laser therapy, 808 nm, 4 infrared diodes, 180 mW, 9 J. In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
Study NCT04020861 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TENS
Description: To active transcutaneous electrical nerve stimulation (TENS) the patient will be oriented to lie preferably in prone. Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. It will be used the following parameters: frequency of 100 Hz, pulse duration of 125 µs (positive phase), 30 minutes of current stimulation and the pulse amplitude will be increased until the patient reports a strong but comfortable paresthesia (including motor level stimulation but no painful TENS). The amplitude will be adjusted (if necessary) each 5 minutes to keep a strong but comfortable paresthesia.
Study NCT04020861 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBM
Description: In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
Study NCT04020861 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo PBM
Description: In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
Study NCT04020861 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo TENS
Description: To placebo transcutaneous electrical nerve stimulation (TENS) Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. This device was customized to deliver a current for 30 seconds (both channels) and then ramp off over the next 15 seconds so that it will be active for a total of 45 seconds. This will permit the patient to fell the TENS sensation while applying the settings.
Study NCT04020861 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TENS
Description: To placebo transcutaneous electrical nerve stimulation (TENS) Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. This device was customized to deliver a current for 30 seconds (both channels) and then ramp off over the next 15 seconds so that it will be active for a total of 45 seconds. This will permit the patient to fell the TENS sensation while applying the settings.
Study NCT02711267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Zovirax® cream
Description: (manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)
Study NCT02711267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Aciclostad cream
Description: (STADA Arzneimittel GmbH, Vienna, Austria)
Study NCT02711267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Aciclovir cream 1A Pharma
Description: (1A Pharma GmbH, Vienna, Austria)
Study NCT02711267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Zovirax Cold Sore Cream
Description: (GlaxoSmithKline Consumer Health Care, Brendfort, UK; Marketing authorization holder: Beeham Group PLC, Brendfort, UK)
Study NCT03473132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: four factor prothrombin complex concentrate
Description: After treatment with 4F-PCC, coagulation factor levels will be assessed. Time to return to anticoagulation target INR will also be determined.
Study NCT03976622 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Blood samples: serum and PBMC
Study NCT02711267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Zovirax® cream (Austria)
Description: (GlaxoSmithKline Pharma GmbH, Vienna, Austria)
Study NCT02711267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OFM
Description: Sampling method for interstitial fluid
Study NCT02711267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFM Probe
Description: Sampling probe used during OFM
Study NCT02711267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFM Pump
Description: Pump used to operate OFM probes